Featured Research

from universities, journals, and other organizations

Drug fails to help kidney transplant recipients, study suggests

Date:
January 10, 2013
Source:
American Society of Nephrology
Summary:
While safe and well-tolerated, angiotensin II blockade did not lessen tissue scarring or prevent kidney failure in kidney transplant recipients. Angiotensin II blockade is known to slow kidney disease progression in individuals without transplants.

A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

Related Articles


Immunosuppressants help prolong the function of transplanted organs, but therapies that target non-immunological damage to these organs -- such as elevated blood pressure and tissue scarring (or fibrosis) -- have not been studied.

Angiotensin II blockade, which causes blood vessels to dilate, can slow the progression of kidney disease in individuals without kidney transplants. Hassan Ibrahim, MD (University of Minnesota) and his colleagues set out to test the strategy in transplant recipients. "To our knowledge this is the first randomized placebo-controlled trial of angiotensin II blockade in these patients," said Dr. Ibrahim.

The investigators assigned 153 kidney transplant recipients to receive the angiotensin II receptor blocker losartan or placebo within three months of transplantation, continuing treatment for five years.

"Contrary to what has been observed in native kidney disease, angiotensin II blockade did not demonstrate a statistically significant benefit in lessening fibrosis or terminal kidney failure from severe fibrosis. Nevertheless, angiotensin II blockade was safe and well-tolerated," said Dr. Ibrahim. He noted that a similar trial is ongoing in Canada.

The findings provide valuable information for future studies of non-immunological therapies for kidney transplant recipients.

Study co-authors include Scott Jackson, MS, Jeffrey Connaire, MD, Arthur Matas, MD, Arthur Ney, MD, Ann West, RN, Nicole Lentsch, RN, Jensina Ericksen, Jenny Bodner, RN, Bertram Kasiske, MD, FACP (Hennepin County Medical Center); Behzad Najafian, MD (University of Washington); and Michael Mauer, MD (University of Minnesota).


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hassan N. Ibrahim, Scott Jackson, Jeffery Connaire, Arthur Matas, Arthur Ney, Behzad Najafian, Ann West, Nicole Lentsch, Jensina Ericksen, Jenny Bodner, Bertram Kasiske and Michael Mauer. Angiotensin II Blockade in Kidney Transplant Recipients. JASN, January 10, 2013 DOI: 10.1681/2012080777

Cite This Page:

American Society of Nephrology. "Drug fails to help kidney transplant recipients, study suggests." ScienceDaily. ScienceDaily, 10 January 2013. <www.sciencedaily.com/releases/2013/01/130110212123.htm>.
American Society of Nephrology. (2013, January 10). Drug fails to help kidney transplant recipients, study suggests. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2013/01/130110212123.htm
American Society of Nephrology. "Drug fails to help kidney transplant recipients, study suggests." ScienceDaily. www.sciencedaily.com/releases/2013/01/130110212123.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins